JTCS Medtronic Endurant
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reves, J. G.
Right arrow Articles by VanTrigt, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reves, J. G.
Right arrow Articles by VanTrigt, P.

The Journal of Thoracic and Cardiovascular Surgery, Vol 100, 221-227, Copyright © 1990 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association


ARTICLES

Esmolol for treatment of intraoperative tachycardia and/or hypertension in patients having cardiac operations. Bolus loading technique

JG Reves, ND Croughwell, E Hawkins, LR Smith, JR Jacobs, S Rankin, J Lowe and P VanTrigt
Department of Anesthesiology, Heart Center, Duke University Medical Center, Durham, NC 27710.

Esmolol, administered as a bolus followed by continuous infusion, was used to treat the occurrence of transient tachycardia and hypertension or tachycardia alone before cardiopulmonary bypass in 45 patients. The study was conducted in two phases. Phase I (15 patients) was a dose- finding study and phase II (30 patients) was a randomized, double- blind, placebo-controlled efficacy study. All patients received the last dose of their usual beta-adrenergic blocker the night before the operation and were anesthetized with midazolam, vecuronium, and enflurane in oxygen. Treatment criteria were either a systolic blood pressure greater than 140 mm Hg and a heart rate greater than 70 or a heart rate greater than 80 beats/min. In phase I, graduated doses of esmolol were given to successive patients. A dose of 80 mg followed by a 12 mg/min infusion was declared effective. Phase II patients were randomized to receive esmolol (n = 16) or placebo (n = 14). Hemodynamic data were collected at baseline and 1, 3, 5, and 10 minutes after the administration of esmolol. Plasma norepinephrine was measured at baseline, 1, and 10 minutes. Esmolol significantly (p less than 0.05) reduced heart rate at 1, 3, 5, and 10 minutes but did not change blood pressure, pulmonary artery diastolic pressure, right atrial pressure, cardiac output, or systemic vascular resistance. Our results show that a bolus loading dose of esmolol is safe and effective in the treatment of tachycardia in patients with ischemic heart disease and that esmolol rapidly blocks the beta-adrenergic effects of norepinephrine associated with surgical stress.


This article has been cited by other articles:


Home page
Anesth. Analg.Home page
F. Wiesbauer, O. Schlager, H. Domanovits, B. Wildner, G. Maurer, M. Muellner, H. Blessberger, and M. Schillinger
Perioperative {beta}-Blockers for Preventing Surgery-Related Mortality and Morbidity: A Systematic Review and Meta-Analysis
Anesth. Analg., January 1, 2007; 104(1): 27 - 41.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
P. F. White, B. Wang, J. Tang, R. H. Wender, R. Naruse, and A. Sloninsky
The Effect of Intraoperative Use of Esmolol and Nicardipine on Recovery After Ambulatory Surgery
Anesth. Analg., December 1, 2003; 97(6): 1633 - 1638.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
D. B. Wiest, S. S. Garner, W. E. Uber, and R. M. Sade
Esmolol for the management of pediatric hypertension after cardiac operations
J. Thorac. Cardiovasc. Surg., April 1, 1998; 115(4): 890 - 897.
[Abstract] [Full Text] [PDF]


Home page
Otolaryngol Head Neck SurgHome page
M. Kalyanaraman, R. L. Carpenter, M. J. McGlew, and S. R. Guertin
Cardiopulmonary compromise after use of topical and submucosal {alpha}-agonists: Possible added complication by the use of {beta}-blocker therapy
Otolaryngology -- Head and Neck Surgery, July 1, 1997; 117(1): 56 - 61.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1990 by The American Association for Thoracic Surgery.